John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Safety of immunosuppressants in Crohn’s disease: focus on methotrexate Volume 29, issue 7, September 2022

Tables

Author
CHU d’Amiens, Université de Picardie, Service d’hépato-gastroentérologie, Rond point du Cabrol, 80054 Amiens
Correspondance : M. Fumery

The methotrexate is an immunosuppressant administered subcutaneously indicated as monotherapy in moderate Crohn’s disease. Methotrexate can also be used in combination with an anti-TNF, to improve its pharmacokinetics. Before its prescription, it is necessary to check the absence of contraindications. Particular attention should be given to the use of MTX in young women of childbearing potential, due to a risk of associated fetal malformation. To prevent the risk of toxicity, folate supplementation must be systematic and biological monitoring is recommended.